Boston Scientific reported second-quarter revenue of $5.06 billion, exceeding the $4.89 billion analysts expected, as sales rose 23 percent from a year earlier. Adjusted earnings climbed to $0.75 a share, beating the $0.72 consensus, while GAAP net income more than doubled to $795 million, or $0.53 a share. Growth was led by continued demand for heart-care devices. Cardiovascular revenue increased 26.8 percent year-on-year, buoyed by the FARAPULSE pulsed-field ablation system and the WATCHMAN left-atrial appendage closure device. U.S. sales advanced 30.7 percent, helping offset currency headwinds in Europe and emerging markets. On the strength of the quarter, the company raised its full-year 2025 adjusted earnings forecast to $2.95–$2.99 a share from $2.87–$2.94 and projected third-quarter adjusted profit of $0.70–$0.72 a share. Boston Scientific now targets reported revenue growth of roughly 18–19 percent for the year. The Massachusetts-based device maker also secured U.S. regulatory clearance to expand FARAPULSE labeling to persistent atrial fibrillation, received a CE mark for the next-generation WATCHMAN FLX Pro, and closed the acquisitions of Intera Oncology and SoniVie to widen its oncology and hypertension offerings.